Ziyan Wang, Jiao An, Kunpeng Liu, Pin Yu, Xin Fang, Jiadai Li, Hua Zhu, Qianjun Zhu, Chuanqi Huang, Chao Zhang, Binbin Zhao, Linlin Bao, Yujiao Song, Xiayao Cao, Dongdong Hu, Yuanxiang Jiang, Likang Shi, Lingyun Zhou, Jiang Fan, Wuxiang Guan, Chenliang Zhou, Zhongyu Hu, Zhiming Yuan, Jiangning Liu, Chao Shan, Ge Liu
Since the first outbreak in December 2019, SARS-CoV-2 has been constantly evolving and five variants have been classified as Variant of Concern (VOC) by the World Health Organization (WHO). These VOCs were found to enhance transmission and/or decrease neutralization capabilities of monoclonal antibodies and vaccine-induced antibodies. Here, we successfully designed and produced a recombinant COVID-19 vaccine in CHO cells at a high yield. The vaccine antigen contains four hot spot substitutions, K417N, E484K, N501Y and D614G, based on a prefusion-stabilized spike trimer of SARS-CoV-2 (S-6P) and formulated with an Alum/CpG 7909 dual adjuvant system...
November 12, 2022: NPJ Vaccines